An interventional study of Physical training in Breast Cancer, sponsored by Karolinska Institutet. Recruiting at 13 sites in 4 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2025-09-22.
Sponsored by Karolinska Institutet · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Breast Neoplasms by Karolinska Institutet — 4 open to participants now, 6 under way, 2 of them phase 3. Breast Neoplasms · Karolinska Institutet.
Among the 19 studies in Breast Neoplasms by Karolinska Institutet, this one is the 6th largest by planned enrollment of the 18 interventional ones that give a count, is one of 3 that started in 2022, is one of 13 with no phase, and was the 13th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →4 of the 19 studies in Breast Neoplasms by Karolinska Institutet are open now, in 5 countries. Recruiting first, the newest first:
Karolinska Institutet · Sites in Finland, Korea, Republic of, Sweden
Ages 18+
Karolinska Institutet · Sites in Sweden
Ages 18+ · Women only
Karolinska Institutet
Ages 40–74 · Women only · Healthy volunteers
By country, each count listing its studies:
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 3
First in 1977; this study’s year is marked. 3 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 712 is above the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Median enrollment 175 across the 18 interventional studies, 35,002 across the 1 observational. Of the 10 that completed or were terminated, 1 (10%) have results posted.
This tab as a report to print or save as PDF → With an account.
Karolinska Institutet is the lead sponsor of 1,150 studies on the registry; 276 are open to participants now.
1 of the studies in Breast Neoplasms by Karolinska Institutet that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06471452Karolinska InstitutetTo Live Better After Breast Cancer Treatment | 2027-06 |
Add it to your calendar (.ics) → With an account.
Among the 19 studies in Breast Neoplasms by Karolinska Institutet, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Neoadjuvant chemotherapy (NACT) is increasingly used in breast cancer. The best proof of NACT efficacy is pathological complete response (pCR), i.e. the absence of invasive tumour on post-NACT surgical histopathology. While it is known that physical exercise can help patients to better tolerate and complete often harsh cancer treatments, it is an emerging area of research to understand if and how exercise exerts anti-tumour effects and improves oncological outcomes.
The main aim of the Neo-ACT trial is to examine if a physical exercise intervention during NACT can increase pCR rates in breast cancer. Secondary aims are residual cancer burden, radiological tumour response, patient-related outcomes (health-related quality of life, physical activity), physiological outcomes (muscle strength, cardiorespiratory fitness), cancer treatment-related toxicities (cognitive dysfunction, chemotherapy completion rates) and long-term sick leave. Furthermore, the trial will explore how physical exercise affects anti-tumoral mechanisms inherent to therapy or host by hypothesis-generating translational analyses.
712 patients with primary invasive breast cancer will be randomized to either a supervised intervention of high-intensity interval and resistance training during NACT, supported by an exercise app, or to usual care, and followed for two years. Physical activity is meticulously tracked. By offering patients active involvement, the trial contributes strongly to the concept of personalized medicine.
The Neo-ACT assesses the primary endpoint pathological complete response (pCR) and the secondary endpoints Residual Cancer Burden (RCB), objective tumour response (RECIST), all-cause, breast cancer-specific, and recurrence-free survival at 2, 5 and 10 years, health-related quality of life assessed by the EORTC QLQ-C30 and BR23 questionnaires, self-reported physical activity (Modified Godin Leisure Time Physical activity questionnaire), toxicity-related outcomes (chemotherapy completion rates, number of unplanned hospital admissions during NACT, objective cognitive dysfunction (Amsterdam Cognition Scan), cardiac toxicity and sick leave), device-measured physical activity level (Fitbit activity tracker), muscle strength (handgrip strength test and hypothetical 1-RM maximal leg muscle strength tests), and cardiorespiratory fitness (Ekblom-Bak submaximal cycle test).
Participants randomized to the exercise group will complete 120 min exercise sessions per week from initiation of NACT to surgery (approx. five months):
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Routine information on the benefit of physical activity
High-intensity interval and strength training during neoadjuvant chemotherapy
Behavioral: Physical training
Participants randomized to the exercise group will complete two structured 60-min exercise sessions per week from initiation of NACT to surgery (approx. five months).
Pathological complete response
Absence of residual invasive tumor in breast and axilla at surgery
Time frame: 5-6 months
Global health-related quality of life
assessed by the EORTC QLQ-C30 questionnaire
Time frame: baseline, after 1 and 2 years
Breast cancer-related quality of life
assessed by the EORTC QLQ-B23 questionnaire
Time frame: baseline, after 1 and 2 years
Self-reported physical activity
Modified Godin Leisure Time Physical activity questionnaire
Time frame: baseline, pre-surgery, 1- and 2-year follow-up
Chemotherapy completion rate
proportion of participants receiving the planned number of treatments
Time frame: 1 year
Cumulative chemotherapy dosage
total dose of NACT received to account for potential dose reduction
Time frame: 1 year
Objective cognitive dysfunction
online neuropsychological test (Amsterdam Cognition Scan)
Time frame: baseline and 1 year
Sick leave
Patient-reported absence from work
Time frame: pre-surgery and at 1- and 2-year follow-up
Device-measured physical activity level
Fit-bit tracker
Time frame: baseline and 5-6months (pre surgery)
Muscle strength
hypothetical 1-RM maximal leg muscle strength test
Time frame: baseline and 5-6 months
Handgrip strength
handgrip strength test
Time frame: baseline and 5-6 months
Cardiorespiratory fitness
Åstrand submaximal cycle test
Time frame: baseline and 5-6 months (pre-surgery)
Radiological tumour response
RECIST
Time frame: 5-6 months
Residual Cancer Burden (RCB)
Degree of tumor response to NACT
Time frame: 5-6 months
Plan to share: Yes — IPD will be available after study completion upon reasonable request submitted to the PI and with all legal and ethical requirements being fulfilled.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: Study protocol, SAP and ICF available on trial homepage presently. Open access. CSR and analytic code available on request, see above.
Data sharing details ↗ · ki.se
Started Nov 2022 (actual). Primary completion is estimated for Dec 2027, 61 months after the start.
Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 61 months is above that.
Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.